Bedaquiline: Current status and future perspectives

Saeed Khoshnood; Mehdi Goudarzi; Elahe Taki; Atieh Darbandi; Ebrahim Kouhsari; Mohsen Heidary; Moloudsadat Motahar; Melika Moradi; Hadi Bazyar

doi:10.1016/j.jgar.2021.02.017

Bedaquiline: Current status and future perspectives

J Glob Antimicrob Resist. 2021 Jun:25:48-59. doi: 10.1016/j.jgar.2021.02.017. Epub 2021 Mar 5.

Authors

Saeed Khoshnood¹, Mehdi Goudarzi², Elahe Taki³, Atieh Darbandi⁴, Ebrahim Kouhsari⁵, Mohsen Heidary⁶, Moloudsadat Motahar⁷, Melika Moradi⁷, Hadi Bazyar⁸

Affiliations

¹ Clinical MicrobiologyResearch Center, Ilam University of Medical Sciences, Ilam, Iran.
² Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
³ Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
⁵ Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
⁶ Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran; Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran. Electronic address: mohsenheidary40@gmail.com.
⁷ Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
⁸ Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

PMID: 33684606
DOI: 10.1016/j.jgar.2021.02.017

Abstract

The development of drug-resistant tuberculosis (TB) is a major threat worldwide. Based on World Health Organization (WHO) reports, it is estimated that more than 500 000 new cases of drug-resistant TB occur annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore, new options for TB therapy are required. Bedaquiline (BDQ), a novel anti-TB drug, has significant minimum inhibitory concentrations (MICs) both against drug-susceptible and drug-resistant TB. Moreover, BDQ was recently approved for therapy of MDR-TB. The current narrative review summarises the available data on BDQ resistance, describes its antimicrobial properties, and provides new perspectives on clinical use of this novel anti-TB agent.

Keywords: Bedaquiline; Multidrug resistance; Mycobacterium tuberculosis; Tuberculosis.

Publication types

Review

MeSH terms

Antitubercular Agents / pharmacology
Antitubercular Agents / therapeutic use
Diarylquinolines / therapeutic use
Extensively Drug-Resistant Tuberculosis* / drug therapy
Humans
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antitubercular Agents
Diarylquinolines
bedaquiline